DRMAW - Dermata Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

DRMAW

DERMATA THERAPEUTICS, INC.

NASDAQ

$0.00

▼ DOWN 50.00% (-0.00)

KEY STATISTICS

Market Cap$409.00

52w High$0.02

52w Low$0.00

Dividend Yield—

Frequency—

P/E—

Volume0

Shares Out.681.56K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Gerald T. Proehl

COMPENSATION 2026

Salary$280,000

Stock Awards$52,515

Incentive Plan Pay$0

All Other Comp.$0

Total$472,515

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 13, 2021

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 18, 2026

DayWednesday

Rev. Est.$25.00K

NOV

WED

PRICE

$0.00 ▲ UP 48.35% (+$73.38)

—

No price history available for DRMAW over this range.

About Dermata Therapeutics, Inc.

https://www.dermatarx.com ↗

Dermata Therapeutics, a San Diego-based biotech founded in 2014, develops topical treatments like DMT310 for skin conditions such as acne and psoriasis, and DMT410 for hyperhidrosis and aesthetic uses.

INDUSTRY

Biotechnology

A PRODUCT DERMATA THERAPEUTICS, INC. IS KNOWN FOR

Once-Weekly Acne Kit

Dermata Therapeutics' upcoming once-weekly OTC acne treatment kit, launching mid-2026, features proprietary Spongilla technology and FDA-approved ingredients, marking a strategic shift into the consumer skincare market.